The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024
May 30, 2024 at 04:26 pm
Share
The Cooper Companies, Inc. raised earnings guidance for the fiscal year 2024. For the year, the company expects total revenue of $3,863 million - $3,905 million (organic growth of 7.5% to 8.5%),
CVI revenue of $2,591 - $2,613 million (organic growth of 8.5% to 9.5%) and CSI revenue of $1,272 - $1,292 million (organic growth of 5% to 7%).
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVisionâs products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and womenâs health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within womenâs health. CooperSurgicalâs brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.
THE COOPER COMPANIES, INC. 
